Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBITDA (2016 - 2025)

Haemonetics (HAE) has 17 years of EBITDA data on record, last reported at $67.4 million in Q4 2025.

  • For Q4 2025, EBITDA rose 307.05% year-over-year to $67.4 million; the TTM value through Dec 2025 reached $251.1 million, up 109.64%, while the annual FY2025 figure was $221.8 million, 34.53% up from the prior year.
  • EBITDA reached $67.4 million in Q4 2025 per HAE's latest filing, up from $58.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $71.3 million in Q1 2025 and bottomed at -$21.2 million in Q2 2021.
  • Average EBITDA over 5 years is $30.9 million, with a median of $30.6 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 181.42% in 2021, then surged 427.28% in 2022.
  • A 5-year view of EBITDA shows it stood at $14.4 million in 2021, then surged by 159.36% to $37.4 million in 2022, then rose by 5.79% to $39.6 million in 2023, then tumbled by 58.15% to $16.6 million in 2024, then soared by 307.05% to $67.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $67.4 million in Q4 2025, $58.5 million in Q3 2025, and $53.9 million in Q2 2025.